Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens. Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI) will be higher in the pandemic time period (Pandemic, March 2020 - February 2025) compared to the pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).
Study Type
OBSERVATIONAL
Enrollment
400
Methodist Dallas Medical Center
Dallas, Texas, United States
Incidence of third generation cephalosporin-resistant bacteria (3GCRB)
Incidence of third generation cephalosporin-resistant bacteria (3GCRB)
Time frame: 5 Months
Incidence of ESBLPE
Incidence of ESBLPE
Time frame: 5 months
Incidence of CRB
Incidence of CRB
Time frame: 5 Months
Incidence of other pathogens
* MRSA * VRE * CDI
Time frame: August 2021
Incidence of nosocomial infections
* Catheter-associated urinary tract infection (CAUTI) * Central line-associated bloodstream infection (CLABSI) * Possible ventilator-associated pneumonia (PVAP)
Time frame: 5 Months
Incidence of clinical outcomes
death, recovery, long-term care facility, etc.
Time frame: 5 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.